{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T23:09:40Z","timestamp":1773011380643,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejca.2019.08.030","type":"journal-article","created":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T04:57:55Z","timestamp":1570078675000},"page":"172-176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Nivolumab-related mucous membrane pemphigoid"],"prefix":"10.1016","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2585-6633","authenticated-orcid":false,"given":"Vincent","family":"Sibaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuelle","family":"Vigarios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Siegfried","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chloe","family":"Bost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecile","family":"Pages-Laurent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2019.08.030_bib1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2019.08.030_bib2","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2019.08.030_bib3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib4","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2019.08.030_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jaad.2018.07.008","article-title":"Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy","volume":"79","author":"Siegel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib6","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1158\/2326-6066.CIR-15-0123","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ejca.2019.08.030_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/CJI.0000000000000280","article-title":"A severe, refractory case of mucous membrane pemphigoid after treatment with pembrolizumab: brief communication","author":"Bezinelli","year":"2019","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2019.08.030_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fmed.2018.00268","volume":"5","author":"Zumelzu","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.ejca.2019.08.030_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/bjd.16780","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib11","doi-asserted-by":"crossref","DOI":"10.1111\/ced.13996","article-title":"Mucous membrane pemphigoid and oral blistering diseases","author":"Carey","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jaad.2017.05.056","article-title":"Desquamative gingivitis: clinical findings and diseases","volume":"78","author":"Maderal","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2019.08.030_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2019.08.030_bib14","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejca.2019.08.030_bib15","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1111\/jdv.14284","article-title":"Oral lichenoid reactions associated with anti-PD-1\/PD-L1 therapies: clinicopathological findings","volume":"31","author":"Sibaud","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2019.08.030_bib16","first-page":"742","article-title":"Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma","volume":"15","author":"Schmidgen","year":"2017","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919305003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919305003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:26:30Z","timestamp":1760732790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919305003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":16,"alternative-id":["S0959804919305003"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.08.030","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nivolumab-related mucous membrane pemphigoid","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}